HAI Abraxane With Gemcitabine and Bevacizumab

• Status: Completed
• Trial end date: 2014-05-01

Summary

The goal of this clinical research study is to find the highest tolerable dose of Abraxane® (nab-paclitaxel) when given directly into the liver, in combination with Gemzar® (gemcitabine) and Avastin® (bevacizumab) when given by vein.

• Phase: Phase 1

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Treatments: Albumin-Bound Paclitaxel; Antibodies; Antibodies, Monoclonal; Bevacizumab; Gemcitabine; Lenograstim; Paclitaxel